FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165139474> ?p ?o ?g. }

• W2165139474 endingPage "1788" @default.
• W2165139474 startingPage "1782" @default.
• W2165139474 abstract "National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31.Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay. A predefined cut point for the predictive model was tested in the confirmation cohort. Gene-by-treatment interaction was tested with Cox models, and correlations between variables were assessed with Spearman correlation. Principal component analysis was performed on the final set of selected genes. All statistical tests were two-sided.Eight predictive genes associated with HER2 (ERBB2, c17orf37, GRB7) or ER (ESR1, NAT1, GATA3, CA12, IGF1R) were selected for model building. Three-dimensional subset treatment effect pattern plot using two principal components of these genes was used to identify a subset with no benefit from trastuzumab, characterized by intermediate-level ERBB2 and high-level ESR1 mRNA expression. In the confirmation set, the predefined cut points for this model classified patients into three subsets with differential benefit from trastuzumab with hazard ratios of 1.58 (95% confidence interval [CI] = 0.67 to 3.69; P = .29; n = 100), 0.60 (95% CI = 0.41 to 0.89; P = .01; n = 449), and 0.28 (95% CI = 0.20 to 0.41; P < .001; n = 442; P(interaction) between the model and trastuzumab < .001).We developed a gene expression-based predictive model for degree of benefit from trastuzumab and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastuzumab in HER2-negative patients (NSABP B-47)." @default.
• W2165139474 created "2016-06-24" @default.
• W2165139474 creator A5001165417 @default.
• W2165139474 creator A5001668085 @default.
• W2165139474 creator A5002068827 @default.
• W2165139474 creator A5006092979 @default.
• W2165139474 creator A5007363746 @default.
• W2165139474 creator A5009480096 @default.
• W2165139474 creator A5011100408 @default.
• W2165139474 creator A5017943772 @default.
• W2165139474 creator A5025438428 @default.
• W2165139474 creator A5029495209 @default.
• W2165139474 creator A5033033849 @default.
• W2165139474 creator A5033628191 @default.
• W2165139474 creator A5034204447 @default.
• W2165139474 creator A5040393015 @default.
• W2165139474 creator A5049016680 @default.
• W2165139474 creator A5054716670 @default.
• W2165139474 creator A5055013606 @default.
• W2165139474 creator A5059700887 @default.
• W2165139474 creator A5060196610 @default.
• W2165139474 creator A5060592779 @default.
• W2165139474 creator A5063504632 @default.
• W2165139474 creator A5063900632 @default.
• W2165139474 creator A5067203408 @default.
• W2165139474 creator A5073338995 @default.
• W2165139474 creator A5074132480 @default.
• W2165139474 creator A5074479466 @default.
• W2165139474 creator A5079315515 @default.
• W2165139474 creator A5082509731 @default.
• W2165139474 creator A5058113641 @default.
• W2165139474 date "2013-11-22" @default.
• W2165139474 modified "2023-10-18" @default.
• W2165139474 title "Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31" @default.
• W2165139474 cites W1995830102 @default.
• W2165139474 cites W2017263519 @default.
• W2165139474 cites W2025002326 @default.
• W2165139474 cites W2034948055 @default.
• W2165139474 cites W2065417289 @default.
• W2165139474 cites W2068326740 @default.
• W2165139474 cites W2080661875 @default.
• W2165139474 cites W2093322080 @default.
• W2165139474 cites W2098544382 @default.
• W2165139474 cites W2105882193 @default.
• W2165139474 cites W2117984780 @default.
• W2165139474 cites W2128402413 @default.
• W2165139474 cites W2132619562 @default.
• W2165139474 cites W2134148782 @default.
• W2165139474 cites W2146384083 @default.
• W2165139474 cites W2147767711 @default.
• W2165139474 cites W2149908785 @default.
• W2165139474 cites W2153158488 @default.
• W2165139474 cites W2157285286 @default.
• W2165139474 cites W2318605753 @default.
• W2165139474 cites W4229626909 @default.
• W2165139474 doi "https://doi.org/10.1093/jnci/djt321" @default.
• W2165139474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3848987" @default.
• W2165139474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24262440" @default.
• W2165139474 hasPublicationYear "2013" @default.
• W2165139474 type Work @default.
• W2165139474 sameAs 2165139474 @default.
• W2165139474 citedByCount "92" @default.
• W2165139474 countsByYear W21651394742013 @default.
• W2165139474 countsByYear W21651394742014 @default.
• W2165139474 countsByYear W21651394742015 @default.
• W2165139474 countsByYear W21651394742016 @default.
• W2165139474 countsByYear W21651394742017 @default.
• W2165139474 countsByYear W21651394742018 @default.
• W2165139474 countsByYear W21651394742019 @default.
• W2165139474 countsByYear W21651394742020 @default.
• W2165139474 countsByYear W21651394742021 @default.
• W2165139474 countsByYear W21651394742022 @default.
• W2165139474 countsByYear W21651394742023 @default.
• W2165139474 crossrefType "journal-article" @default.
• W2165139474 hasAuthorship W2165139474A5001165417 @default.
• W2165139474 hasAuthorship W2165139474A5001668085 @default.
• W2165139474 hasAuthorship W2165139474A5002068827 @default.
• W2165139474 hasAuthorship W2165139474A5006092979 @default.
• W2165139474 hasAuthorship W2165139474A5007363746 @default.
• W2165139474 hasAuthorship W2165139474A5009480096 @default.
• W2165139474 hasAuthorship W2165139474A5011100408 @default.
• W2165139474 hasAuthorship W2165139474A5017943772 @default.
• W2165139474 hasAuthorship W2165139474A5025438428 @default.
• W2165139474 hasAuthorship W2165139474A5029495209 @default.
• W2165139474 hasAuthorship W2165139474A5033033849 @default.
• W2165139474 hasAuthorship W2165139474A5033628191 @default.
• W2165139474 hasAuthorship W2165139474A5034204447 @default.
• W2165139474 hasAuthorship W2165139474A5040393015 @default.
• W2165139474 hasAuthorship W2165139474A5049016680 @default.
• W2165139474 hasAuthorship W2165139474A5054716670 @default.
• W2165139474 hasAuthorship W2165139474A5055013606 @default.
• W2165139474 hasAuthorship W2165139474A5058113641 @default.
• W2165139474 hasAuthorship W2165139474A5059700887 @default.
• W2165139474 hasAuthorship W2165139474A5060196610 @default.
• W2165139474 hasAuthorship W2165139474A5060592779 @default.
• W2165139474 hasAuthorship W2165139474A5063504632 @default.
• W2165139474 hasAuthorship W2165139474A5063900632 @default.
• W2165139474 hasAuthorship W2165139474A5067203408 @default.

• next